Subscribe
wk1003mike / Shutterstock.com
1 May 2025NewsAmericasMarisa Woutersen

US warns of rising counterfeit drug threat from India and China

Latest report highlights increasing concerns over counterfeit pharmaceuticals, IP barriers, and market access challenges | Key countries to watch include India, China, the UAE, and Singapore | Report also outlines challenges in Mexico, Russia, Brazil, and Indonesia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

More on this story

Europe
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
22 April 2025   Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025   Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion.

More features

Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors
UPC issues first decision on second medical use
Mayer Brown welcomes patent litigator in Washington, DC
LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025